Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY).
Ninomiya K, Hata T, Yoshioka H, Ohashi K, Bessho A, Hosokawa S, Ishikawa N, Yamasaki M, Shibayama T, Aoe K, Kozuki T, Harita S, Ueda Y, Murakami T, Fujimoto N, Yanai H, Toyooka S, Takata M, Hotta K, Kiura K; HER2-CS Network. Ninomiya K, et al. Among authors: hata t. Chest. 2019 Aug;156(2):357-366. doi: 10.1016/j.chest.2019.01.011. Epub 2019 May 6. Chest. 2019. PMID: 31072612
Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy.
Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Hata T, Kim YH, Tomii K, Ishida T, Hirabayashi M, Hara S, Ishitoko M, Fukuda Y, Hwang MH, Sakai N, Fukui M, Nakaji H, Morita M, Mio T, Yasuda T, Sugita T, Hirai T. Fujimoto D, et al. Among authors: hata t. J Thorac Oncol. 2019 Mar;14(3):468-474. doi: 10.1016/j.jtho.2018.10.167. Epub 2018 Nov 20. J Thorac Oncol. 2019. PMID: 30468872 Free article.
A randomized trial of sodium alginate prevention of esophagitis in LA-NSCLC receiving chemoradiotherapy: OLCSG1401.
Ninomiya K, Yokoyama T, Hotta K, Oze I, Katsui K, Hata T, Yoshioka H, Bessho A, Hosokawa S, Kuyama S, Kudo K, Kozuki T, Harada D, Yasugi M, Murakami T, Nakanishi M, Takigawa N, Maeda Y, Kiura K; Okayama Lung Cancer Study Group. Ninomiya K, et al. Among authors: hata t. Support Care Cancer. 2021 Sep;29(9):5237-5244. doi: 10.1007/s00520-021-06092-1. Epub 2021 Mar 1. Support Care Cancer. 2021. PMID: 33649919 Clinical Trial.
Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study.
Hata T, Sakaguchi C, Hirano K, Kobe H, Ishida M, Nakano T, Tachibana Y, Tamiya N, Shiotsu S, Takeda T, Yamada T, Yokoyama T, Tsuchiya M, Nagasaka Y. Hata T, et al. J Cancer Res Clin Oncol. 2023 Jun;149(6):2475-2482. doi: 10.1007/s00432-022-04125-8. Epub 2022 Jun 23. J Cancer Res Clin Oncol. 2023. PMID: 35737092
Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR-TKI in non-small cell lung cancer patients with EGFR mutation: A multicenter retrospective study.
Hata T, Sakaguchi C, Hirano K, Kobe H, Ishida M, Nakano T, Tachibana Y, Tamiya N, Shiotsu S, Takeda T, Yamada T, Yokoyama T, Tsuchiya M, Nagasaka Y. Hata T, et al. Thorac Cancer. 2023 Apr;14(11):1004-1011. doi: 10.1111/1759-7714.14836. Epub 2023 Mar 3. Thorac Cancer. 2023. PMID: 36866788 Free PMC article.
BRAF V600E-induced distinct DNA damage response defines the therapeutic potential of p53 activation for TP53 wild-type colorectal cancer.
Tokuyama S, Kato H, Takahashi H, Ueda K, Arita A, Ueda R, Seto H, Sekido Y, Hata T, Hamabe A, Ogino T, Miyoshi N, Uemura M, Matsuoka K, Tsukamoto O, Yamamoto H, Doki Y, Eguchi H, Takashima S. Tokuyama S, et al. Among authors: hata t. Carcinogenesis. 2024 Jun 13:bgae040. doi: 10.1093/carcin/bgae040. Online ahead of print. Carcinogenesis. 2024. PMID: 38868979
2,114 results